Bifogade filer
Kurs
-2,84%
Likviditet
0,94 MNOK
Kalender
Tid* | ||
2025-08-28 | N/A | Kvartalsrapport 2025-Q2 |
2025-06-05 | N/A | Årsstämma |
2025-04-10 | N/A | Bokslutskommuniké 2024 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-06-19 | - | Årsstämma |
2024-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2024-04-25 | - | Bokslutskommuniké 2023 |
2023-10-04 | - | Split CRNA 30:1 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2023-03-09 | - | Extra Bolagsstämma 2023 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-20 | - | Årsstämma |
2022-04-07 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-25 | - | Extra Bolagsstämma 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-18 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-03-18 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2021-03-17 | - | Årsstämma |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-04-30 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2020-04-29 | - | Årsstämma |
2020-03-11 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-04-10 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2019-04-09 | - | Årsstämma |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-01 | - | Kvartalsrapport 2018-Q3 |
2018-08-23 | - | Kvartalsrapport 2018-Q2 |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-04-12 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2018-04-11 | - | Årsstämma |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-04-05 | - | Årsstämma |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-12 | - | Kvartalsrapport 2016-Q1 |
2016-04-14 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2016-04-13 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
Oslo, 21 October 2021: Reference is made to the announcement made by Targovax ASA ("Targovax" or the "Company") 20 October 2021 regarding the appointment of Erik Digman Wiklund as the new CEO of the Company.
The Board of Directors has resolved to grant 250,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 6.59, to Erik Digman Wiklund.
Following the grant of the 250,000 share options referred to above, Erik Digman Wiklund holds no shares and hold 1,000,000 options in the Company.
The options are granted without consideration. Pursuant to the vesting schedule, 25% of the options will vest 12 months after the day of grant (as long as the option holder is entitled to be part of the option program). Thereafter, 1/36 of the remaining options will vest each month as long as the option holder is entitled to be part of the option program, with the first 1/36 vesting 13 months after the day of grant. The exercise price is equal to the volume weighted average trading price of the shares of the Company on Oslo Børs on the date of the grant. Options that have not been exercised will lapse 7 years after the date of grant.
Reference is made to the attached notification of trading for further details.
Notification by Primary Insiders_EDW.pdf (https://mb.cision.com/Public/17093/3437524/bac63c2c8e36d5e2.pdf)
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com (http://javascript:DeCryptX('2g3u3l0k201x3l3n1m3x3q0d2B1u0a0r3j1p1w3d3{0.2e2q0m'))
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com